Wird geladen...
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
BACKGROUND: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the US Food and Drug Administration to treat crizotinib-refractory non-small cell lung cancer. We performed this meta-analysis to synthesize the results of different clinical trials to evaluate the ef...
Gespeichert in:
| Veröffentlicht in: | Onco Targets Ther |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5840301/ https://ncbi.nlm.nih.gov/pubmed/29535535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S156170 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|